10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Abstract
BACKGROUND: During the United Kingdom Prospective Diabetes Study (UKPDS), patients with type 2 diabetes mellitus who received intensive glucose therapy had a lower risk of microvascular complications than did those receiving conventional dietary therapy. We conducted post-trial monitoring to determine whether this improved glucose control persisted and whether such therapy had a long-term effect on macrovascular outcomes. METHODS: Of 5102 patients with newly diagnosed type 2 diabetes, 4209 were randomly assigned to receive either conventional therapy (dietary restriction) or intensive therapy (either sulfonylurea or insulin or, in overweight patients, metformin) for glucose control. In post-trial monitoring, 3277 patients were asked to attend annual UKPDS clinics for 5 years, but no attempts were made to maintain their previously assigned therapies. Annual questionnaires were used to follow patients who were unable to attend the clinics, and all patients in years 6 to 10 were assessed through questionnaires. We examined seven prespecified aggregate clinical outcomes from the UKPDS on an intention-to-treat basis, according to previous randomization categories. RESULTS: Between-group differences in glycated hemoglobin levels were lost after the first year. In the sulfonylurea-insulin group, relative reductions in risk persisted at 10 years for any diabetes-related end point (9%, P=0.04) and microvascular disease (24%, P=0.001), and risk reductions for myocardial infarction (15%, P=0.01) and death from any cause (13%, P=0.007) emerged over time, as more events occurred. In the metformin group, significant risk reductions persisted for any diabetes-related end point (21%, P=0.01), myocardial infarction (33%, P=0.005), and death from any cause (27%, P=0.002). CONCLUSIONS: Despite an early loss of glycemic differences, a continued reduction in microvascular risk and emergent risk reductions for myocardial infarction and death from any cause were observed during 10 years of post-trial follow-up. A continued benefit after metformin therapy was evident among overweight patients. (UKPDS 80; Current Controlled Trials number, ISRCTN75451837.)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The potential risks of intensive glycemic control may be obviated by incorporating agents that are not associated with hypoglycemia, especially in persons with frequent severe hypoglycemia, hypoglycemia unawareness, or a very long duration of DM, and particularly in the presence of established and advanced atherosclerosis, advanced age, and terminal illness.69,70,76–81”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [79]
In the citing paper
“it is worth noting the legacy effects of significant, early glucose lowering on macrovascular and microvascular complications observed in the UKPDS study [3,37].”
In the citing paper
“Although recidivism in glycemia is typically observed across all interventions in diabetes [4,5,6,29] including pharmaceutical interventions [3,37]”
In the citing paper
“Numerous studies have demonstrated the clinical benefits of early achievement of nearnormal glycemic control in individuals with type 1 diabetes and type 2 diabetes (77-83).”
From Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range (2019) · cites this paper as [81]
In the citing paper
“since optimal glycaemic control reduces the risk of both microvascular and macrovascular complications (36, 55).”
From Transforming body composition with semaglutide in adults with obesity and type 2 diabetes mellitus (2024) · cites this paper as [55]
31 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
(1998) · The Lancet · doi:10.1016/s0140-6736(98)07019-6 · Cited by 20,023
Self-citationEuroQol: a new facility for the measurement of health-related quality of life
(1990) · Health Policy · doi:10.1016/0168-8510(90)90421-9 · Cited by 15,736
(2000) · New England Journal of Medicine · doi:10.1056/nejm200001203420301 · Cited by 8,663
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Hansson, L., Zanchetti, A., Carruthers, S. G., Dahlöf, B., Elmfeldt, D., Julius, S., Ménard, J., Rahn, K. H., Wedel, H., & Westerling, S. (1998) · The Lancet · doi:10.1016/s0140-6736(98)04311-6 · Cited by 5,728
Research works printed but not linked: 3
- 1959, Stat Bull Metrop Insur Co, 40, 1
- Nathan DM, 2005, N Engl J Med, 22, 2643
- 1993, N Engl J Med, 329, 997
Cited by
Items 901–1,000 of 1,169
Are targeted therapies for diabetic cardiomyopathy on the horizon?
Tate, M., Grieve, D., & Ritchie, R. H. (2017) · Clinical Science · doi:10.1042/cs20160491 · Cited by 104
Luk, A. O. Y., Hui, E. M. T., Sin, M.-C., Yeung, C.-Y., Chow, W.-S., Ho, A. Y. Y., Hung, H.-F., Kan, E., Ng, C.-M., So, W.-Y., et al. (2017) · Diabetes Care · doi:10.2337/dc16-2354 · Cited by 98
Berkowitz, S. A., Meigs, J. B., & Wexler, D. J. (2013) · Diabetologia · doi:10.1007/s00125-013-3036-4 · Cited by 92
“Second, because there is little diabetes-specific mortality in the first 5 years of diagnosis [23], and thus less opportunity for survival bias to arise, we also conducted an analysis restricted to patients with diabetes of <5 years’ duration.”
Takeuchi, M., Takino, J.-I., & Yamagishi, S.-I. (2010) · Current Drug Targets · doi:10.2174/1389450111009011468 · Cited by 95
Chinese diabetes datasets for data-driven machine learning
Zhao, Q., Zhu, J., Shen, X., Lin, C., Zhang, Y., Liang, Y., Cao, B., Li, J., Liu, X., Rao, W., et al. (2023) · Scientific Data · doi:10.1038/s41597-023-01940-7 · Cited by 129
Real-world assessments of mySugr mobile health app
Debong, F., Mayer, H., & Kober, J. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.0019 · Cited by 95
Weinstock, R. S., Caprio, S., Copeland, K. C., Gidding, S. S., Hirst, K., Katz, L. L., Marcovina, S. M., Nadeau, K. J., & Nathan, D. M. (2013) · Diabetes Care · Cited by 97
The Economic Costs of Diabetes: Is It Time for a New Treatment Paradigm?
Herman, W. H. (2013) · Diabetes Care · doi:10.2337/dc13-0270 · Cited by 90
“Randomized controlled clinical trials have also demonstrated that intensive glycemicmanagement can delay the onset of microvascular, neuropathic, and cardiovascular complications in people with both type 1 and type 2 diabetes, and that the benefits of early intensive treatment persist over time (22,23).”
BackgroundRole of Hyperglycemia-Induced Advanced Glycation End Product (AGE) Accumulation in Atherosclerosis
Yamagishi, S., & Matsui, T. (2018) · Annals of Vascular Diseases · doi:10.3400/avd.ra.18-00070 · Cited by 101
Diabetic heart disease: A clinical update
Rajbhandari, J., Fernandez, C. J., Agarwal, M., Yeap, B. X. Y., & Pappachan, J. M. (2021) · World Journal of Diabetes · doi:10.4239/wjd.v12.i4.383 · Cited by 102
Management of diabetic foot ulcers and the challenging points: An endocrine view
Doğruel, H., Aydemir, M., & Balcı, M. K. (2022) · World Journal of Diabetes · doi:10.4239/wjd.v13.i1.27 · Cited by 109
Non-insulin-based insulin resistance indexes in predicting severity for coronary artery disease
Zhang, Y., Wang, R., Fu, X., & Song, H. (2022) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-022-00967-x · Cited by 102
Sebastião, I., Candeias, E., Santos, M. S., de Oliveira, C. R., Moreira, P. I., & Duarte, A. I. (2014) · Frontiers in Endocrinology · doi:10.3389/fendo.2014.00110 · Cited by 92
“0% reduces microvascular complications by ~30%, and the risk for myocardial infarction and death after 10 years of intensive glucose control in patients with newly diagnosed T2D (52).”
BackgroundConduction Slowing in Diabetic Sensorimotor Polyneuropathy
Dunnigan, S. K., Ebadi, H., Breiner, A., Katzberg, H. D., Lovblom, L. E., Perkins, B. A., & Bril, V. (2013) · Diabetes Care · doi:10.2337/dc13-0746 · Cited by 95
Pfützner, A., Paz‐Pacheco, E., Allen, E., Frederich, R., Chen, R., & for the CV181039 Investigators (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01385.x · Cited by 93
“The promise of earlier benefit is particularly important given recent evidence of the glycaemic ‘legacy effect’ demonstrated by the UKPDS and the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications [23,24].”
BackgroundNanayakkara, N., Ranasinha, S., Gadowski, A. M., Heritier, S. R., Flack, J. R., Wischer, N., Wong, J., & Zoungas, S. (2017) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2017.11.009 · Cited by 94
SGLT2 Inhibitors: Nephroprotective Efficacy and Side Effects
Garofalo, C., Borrelli, S., Liberti, M., Andreucci, M., Conte, G., Minutolo, R., Provenzano, M., & Nicola, L. D. (2019) · Medicina · doi:10.3390/medicina55060268 · Cited by 106
“Similarly, achieving adequate glycemic control only attenuates the risk of new onset DKD [7,8].”
BackgroundGhosh, S., Luo, D., He, W., Chen, J., Su, X., & Huang, H. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104861 · Cited by 102
Kunutsor, S. K., Balasubramanian, V. G., Zaccardi, F., Gillies, C. L., Aroda, V. R., Seidu, S., & Khunti, K. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15511 · Cited by 76
“42 The 44-year follow-up of the UKPDS showed an 11% risk reduction in all-cause mortality with early intensive control with sulphonylurea or insulin, a 25% risk reduction in all-cause mortality and a 31% risk reduction in MI with early intensive control with metformin.”
BackgroundCardiac implications of hypoglycaemia in patients with diabetes – a systematic review
Hanefeld, M., Duetting, E., & Bramlage, P. (2013) · Cardiovascular Diabetology · doi:10.1186/1475-2840-12-135 · Cited by 93
“diagnosed T2D patients [41,42], found no significant reduction in CV complications and higher rates of severe hypoglycaemia with intensive therapy.”
BackgroundResultInfluentialUpdate on biomarkers of glycemic control
Krhač, M., & Lovrenčić, M. V. (2019) · World Journal of Diabetes · doi:10.4239/wjd.v10.i1.1 · Cited by 93
Barnard, K., Parkin, C., Young, A., & Ashraf, M. (2012) · Journal of Diabetes Science and Technology · doi:10.1177/193229681200600117 · Cited by 92
Fejes, Z., Póliska, S., Czimmerer, Z., Káplár, M., Penyige, A., Gál Szabó, G., Debreceni, I. B., Kunapuli, S. P., Kappelmayer, J., & Nagy, B. (2017) · Thrombosis and Haemostasis · doi:10.1160/th16-04-0322 · Cited by 92
“As such, oral glucose tolerance test resulted in elevated soluble P-selectin concentrations – released primarily from platelets – in male subjects with mild DM2 (5), while a decade-long intensive glycaemic control showed a beneficial long-term effect on platelet function and vascular outcomes in a clinical study (6).”
BackgroundRapid paper based colorimetric detection of glucose using a hollow microneedle device
Nicholas, D., Logan, K. A., Sheng, Y., Gao, J., Farrell, S., Dixon, D., Callan, B., McHale, A. P., & Callan, J. F. (2018) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2018.06.002 · Cited by 96
Kloecker, D. E., Davies, M. J., Khunti, K., & Zaccardi, F. (2020) · Annals of Internal Medicine · doi:10.7326/m19-3286 · Cited by 105
Trinacty, C. M., Adams, A. S., Soumerai, S. B., Zhang, F., Meigs, J. B., Piette, J. D., & Ross-Degnan, D. (2009) · BMC Health Services Research · doi:10.1186/1472-6963-9-24 · Cited by 92
“[4-7] Yet, despite the proven benefits of adhering to a prescribed medication regimen, many patients fall short of adherence targets.”
BackgroundMedical Care and Payment for Diabetes in China: Enormous Threat and Great Opportunity
Yang, W., Zhao, W., Xiao, J., Li, R., Zhang, P., Kissimova-Skarbek, K., Schneider, E., Jia, W., Ji, L., Guo, X., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0039513 · Cited by 90
“Documenting access to care is particularly important because complications from DM, which can be devastating, could largely be prevented by wider use of inexpensive generic medicines, such as metformin, sulphonylureas, statins, angiotensin-converting-enzyme (ACE)-inhibitors, and other classes of blood pressure-lowerin…”
BackgroundMedical Antihyperglycaemic Treatment of Type 2 Diabetes Mellitus
Matthaei, S., Bierwirth, R., Fritsche, A., Gallwitz, B., Häring, H.-U., Joost, H.-G., Kellerer, M., Kloos, C., Kunt, T., Nauck, M., et al. (2009) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-0029-1239559 · Cited by 91
“More-over, the 10-year follow-up data from the UKPDS which was published recently attests to the long-term bene fi ts of intensi-fi ed antihyperglycaemic therapy in reducing macrovascular end points such as myocardial infarction ( Holman et al., 2008, EC Ib ).”
Ferreira, J. P., Girerd, N., Bozec, E., Machu, J., Boivin, J., London, G. M., Zannad, F. M., & Rossignol, P. (2016) · Journal of the American Heart Association · doi:10.1161/jaha.116.003529 · Cited by 94
“This paradigm of a gradual continual increase of risk with higher values of a variable is well known in other fields of medicine, for instance, gradually increasing risk of clinical events is observed with higher fasting glucose values, even outside of the range of diabetes definition.(36) This has also been described…”
BackgroundYamagishi, S., Nakamura, N., & Matsui, T. (2017) · Journal of Diabetes · doi:10.1111/1753-0407.12475 · Cited by 89
“that is legacy effects of early glycemic control on the risk of CVD and death in T2DM patients.(41)”
Backgroundfor the VADT Study Group, Agrawal, L., Azad, N., Bahn, G. D., Ge, L., Reaven, P. D., Hayward, R. A., Reda, D. J., & Emanuele, N. V. (2018) · Diabetologia · doi:10.1007/s00125-017-4473-2 · Cited by 92
Cardoso, C. R. L., Leite, N. C., Dib, E., & Salles, G. F. (2017) · Scientific Reports · doi:10.1038/s41598-017-05159-6 · Cited by 104
Yasuda, I., Hasegawa, K., Sakamaki, Y., Muraoka, H., Kawaguchi, T., Kusahana, E., Ono, T., Kanda, T., Tokuyama, H., Wakino, S., et al. (2021) · Journal of the American Society of Nephrology · doi:10.1681/asn.2020081188 · Cited by 95
Guidelines for Secondary Prevention of Myocardial Infarction (JCS 2011): Digest Version
JCS Joint Working Group (2012) · Circulation Journal · doi:10.1253/circj.cj-66-0053 · Cited by 104
Pajvani, U. B., & Accili, D. (2015) · Diabetologia · doi:10.1007/s00125-015-3722-5 · Cited by 97
“While the growing emphasis on tight glucose control has enabled us to decrease the impact of the microvascular complications of the disease, macrovascular complications remain an unmet challenge [3, 47] and continue to account for nearly half of all diabetes-related deaths and care-related costs [48].”
Sobrin, L., Green, T. J., Sim, X., Jensen, R. A., Tai, E. S., Tay, W. T., Wang, J. J., Mitchell, P. L. R., Sandholm, N., Liu, Y., et al. (2011) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.11-7510 · Cited by 100
Mallery, L. H., Ransom, T., Steeves, B., Cook, B., Dunbar, P., & Moorhouse, P. A. (2013) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2013.08.002 · Cited by 99
Hill, C. J., Cardwell, C. R., Patterson, C. C., Maxwell, A. P., Magee, G. M., Young, R. J., Matthews, B. B., O'Donoghue, D. J., & Fogarty, D. G. (2013) · Diabetic Medicine · doi:10.1111/dme.12312 · Cited by 94
Madonna, R., Giovannelli, G., Confalone, P., Renna, F. V., Geng, Y., & Caterina, R. D. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0342-4 · Cited by 93
“Background Hyperglycemia can cause diabetic micro- [1] and macrovascular complications [2] by triggering oxidative stress [3, 4], forming advanced glycation end products (AGEs) [4, 5], increasing the flux of glucose to sorbitol through the polyol and hexosamine pathways [3], activating protein kinase C (PKC) [6], and…”
BackgroundMagliano, D. J., Chen, L., Carstensen, B., Gregg, E. W., Pavkov, M. E., Salim, A., Andes, L. J., Balicer, R., Baviera, M., Chan, J. C. N., et al. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00327-2 · Cited by 91
George, C., Echouffo-Tcheugui, J. B., Jaar, B. G., Okpechi, I. G., & Kengne, A. P. (2022) · BMC Medicine · doi:10.1186/s12916-022-02438-6 · Cited by 91
Cardioprotective Glucose-Lowering Agents and Dementia Risk: A Systematic Review and Meta-Analysis
Seminer, A., Mulihano, A., O’Brien, C., Krewer, F., Costello, M., Judge, C., O’Donnell, M., & Reddin, C. (2025) · JAMA Neurology · doi:10.1001/jamaneurol.2025.0360 · Cited by 91
Cardiorenal diseases in type 2 diabetes mellitus: clinical trials and real-world practice
Lim, L.-L., Chow, E., & Chan, J. C. N. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00776-2 · Cited by 91
Complication characteristics between young-onset type 2 versus type 1 diabetes in a UK population
Song, S. H. (2015) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2014-000044 · Cited by 89
“Despite the short diabetes duration (T1D vs T2D; 2.5±1.2 vs 2.7±1.2 years, p=NS), the prevalence of obesity (T1D vs T2D; 50.6 vs 91.7%, p<0.0005), hypertension (T1D vs T2D; 27.2 vs 44.4%, p=0.029), dyslipidemia (T1D vs T2D; 38.3 vs 76.4%, p<0.0005), and risk factor clustering (T1D vs T2D; 38.3 vs 80.6%, p<0.0005) were…”
BackgroundInfluentialDiagnostik, Therapie und Verlaufskontrolle des Diabetes mellitus im Kindes- und Jugendalter
Neu, A., Bürger-Büsing, J., Danne, T., Dost, A., Holder, M., Holl, R. W., Holterhus, P., Kapellen, T., Karges, B., Kordonouri, O., et al. (2016) · Diabetologie und Stoffwechsel · doi:10.1055/s-0042-111213 · Cited by 91
Persistent Chromatin Modifications Induced by High Fat Diet*
Leung, A., Trac, C., Du, J., Natarajan, R. D., & Schones, D. E. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.711028 · Cited by 98
“Clinical studies examining blood glucose control for diabetic patients have demonstrated that vascular complications can continue to develop long after blood glucose normalization, a phenomenon that was originally termed metabolic memory (2, 3).”
BackgroundMata‐Cases, M., Franch‐Nadal, J., Real, J., & Mauricio, D. (2016) · BMJ Open · doi:10.1136/bmjopen-2016-012463 · Cited by 99
Gabbay, R. A., Kendall, D., Beebe, C., Cuddeback, J., Hobbs, T., Khan, N. D., Leal, S., Miller, E., Novak, L. M., Rajpathak, S. N., et al. (2020) · Clinical Diabetes · doi:10.2337/cd20-0053 · Cited by 92
The trials and tribulations of determining HbA1c targets for diabetes mellitus
Klein, K. R., & Buse, J. B. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-00425-6 · Cited by 97
The Interaction of Diabetes and Tuberculosis: Translating Research to Policy and Practice
van Crevel, R., & Critchley, J. (2021) · Tropical Medicine and Infectious Disease · doi:10.3390/tropicalmed6010008 · Cited by 110
“Some randomised controlled trials of “tight control” (target < 6% HbA1c) among older people with long-standing type 2 diabetes in high-income countries had unexpected, unfavourable outcomes [67].”
BackgroundMancia, G., Kjeldsen, S. E., Kreutz, R., Pathak, A., Grassi, G., & Esler, M. (2022) · Hypertension · doi:10.1161/hypertensionaha.122.19020 · Cited by 85
Satoh, H., Ohira, T., Hosoya, M., Sakai, A., Watanabe, T., Ohtsuru, A., Kawasaki, Y., Suzuki, H., Takahashi, A., Kobashi, G., et al. (2015) · Journal of Diabetes Research · doi:10.1155/2015/627390 · Cited by 91
The Early Treatment of Type 2 Diabetes
Pratley, R. E. (2013) · The American Journal of Medicine · doi:10.1016/j.amjmed.2013.06.007 · Cited by 109
Vischer, U. M., Bauduceau, B., Bourdel‐Marchasson, I., Blicklé, J. F., Constans, T., Fagot‐Campagna, A., Kaloustian, E., Lassman-Vague, V., Lecomte, P., Simon, D., et al. (2009) · Diabetes & Metabolism · doi:10.1016/j.diabet.2009.02.003 · Cited by 98
“[9] Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA.”
BackgroundMetformin: New Preparations and Nonglycemic Benefits
Fujita, Y., & Inagaki, N. (2017) · Current Diabetes Reports · doi:10.1007/s11892-017-0829-8 · Cited by 99
Postprandial glucose spikes, an important contributor to cardiovascular disease in diabetes?
Hanssen, N. M. J., Kraakman, M. J., Flynn, M. C., Nagareddy, P. R., Schalkwijk, C. G., & Murphy, A. J. (2020) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.570553 · Cited by 90
Saremi, A., Howell, S., Schwenke, D. C., Bahn, G., Beisswenger, P. J., Reaven, P. D., & for the VADT Investigators (2017) · Diabetes Care · doi:10.2337/dc16-1875 · Cited by 90
“several studies (6,7) have revealed that people receiving more intensive glucoselowering therapy have a lower incidence of CVD events, even after the glycemic difference between treatment groups is lost.”
BackgroundResultEpigenetic changes in diabetes
Keating, S., & El‐Osta, A. (2013) · Clinical Genetics · doi:10.1111/cge.12121 · Cited by 86
“In accordance with the metabolic memory hypothesis, lower incidence of macrovascular complications in the intensive therapy group was observed when compared to the conventional treatment group 10 years post-trial (40).”
Inagaki, N., Onouchi, H., Maezawa, H., Kuroda, S., & Kaku, K. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70251-7 · Cited by 98
Evidence‐based diabetes care for older people with Type 2 diabetes: a critical review
Sinclair, A. J., Abdelhafiz, A. H., Forbes, A., & Munshi, M. (2019) · Diabetic Medicine · doi:10.1111/dme.13859 · Cited by 88
Oxidative Stress and Its Regulation in Diabetic Retinopathy
Haydinger, C. D., Oliver, G. F., Ashander, L. M., & Smith, J. R. (2023) · Antioxidants · doi:10.3390/antiox12081649 · Cited by 107
Advances in the management of type 2 diabetes in adults
Galindo, R. J., Trujillo, J. M., Wang, C. C. L., & McCoy, R. G. (2023) · BMJ Medicine · doi:10.1136/bmjmed-2022-000372 · Cited by 110
“8 17 20 Therefore, future research is needed to examine the effect of intensive glycaemic control when achieved with newer glucose lowering drugs, which have a lower risk of hypoglycaemia and additional cardio- reno-metabolic benefits.”
BackgroundGagliardino, J. J., Arrechea, V., Assad, D., Gagliardino, G. G., González, L., Lucero, S., Rizzuti, L., Zufriategui, Z., & Clark, C. (2013) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2368 · Cited by 88
SERCA2 Deficiency Impairs Pancreatic β-Cell Function in Response to Diet-Induced Obesity
Tong, X., Kono, T., Anderson‐Baucum, E. K., Yamamoto, W. R., Gilon, P., Lebeche, D., Day, R. N., Shull, G. E., & Evans‐Molina, C. (2016) · Diabetes · doi:10.2337/db16-0084 · Cited by 97
“The ability of the b-cell to continue in this extended state of compensation is finite for a substantial proportion of individuals, and the typical evolution to T2D is characterized by loss of pancreatic b-cell function, mass, and, possibly, identity (2,3).”
BackgroundDiabetic Kidney Disease: Act Now or Pay Later
Atkins, R. C., & Zimmet, P. (2008) · Brazilian Journal of Transplantation · doi:10.1007/s00467-009-1400-x · Cited by 93
“In the United Kingdom Prospective Diabetes Study (UKPDS), the rates of progression of newly diagnosed type 2 diabetics between the stages of normoalbuminuria, microalbuminuria, macroalbuminuria and renal failure were 2-3% per year [11].”
InfluentialThe role of HbA1c in the diagnosis of diabetes mellitus in Australia
D'Emden, M. C., Shaw, J. E., Colman, P. G., Colagiuri, S., Twigg, S. M., Jones, G. R. D., Goodall, I., Schneider, H. G., & Cheung, N. W. (2012) · Medical Journal of Australia · doi:10.5694/mja12.10988 · Cited by 87
Bai, X., Liu, Z., Li, Z., & Yan, D. (2018) · BMJ Open · doi:10.1136/bmjopen-2017-020062 · Cited by 98
Metabolic Memory and Chronic Diabetes Complications: Potential Role for Epigenetic Mechanisms
Intine, R. V. A., & Sarras, M. P. (2012) · Current Diabetes Reports · doi:10.1007/s11892-012-0302-7 · Cited by 97
Shrikhande, G., Scali, S. T., da Silva, C. G., Damrauer, S. M., Csizmadia, E., Putheti, P., Matthey, M., Arjoon, R., Patel, R., Siracuse, J. J., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0014240 · Cited by 96
“9%) is beneficial for reducing micro and macrovascular complications of diabetes [36].”
BackgroundArnouts, P., Bolignano, D., Nistor, I., Bilo, H., Gnudi, L., Heaf, J., & Biesen, W. V. (2014) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gft462 · Cited by 86
“Furthermore, the use of metformin is associated with a lower incidence of macro-vascular complications [13, 14].”
BackgroundSulphonylurea monotherapy for patients with type 2 diabetes mellitus
Hemmingsen, B., Schroll, J. B., Lund, S. S., Wetterslev, J., Gluud, C., Vaag, A., Sonne, D. P., Lundstrøm, L. H., & Almdal, T. P. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009008.pub2 · Cited by 88
RetractedPromise of SGLT2 Inhibitors in Heart Failure: Diabetes and Beyond
Martens, P., Mathieu, C., & Verbrugge, F. H. (2017) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-017-0522-x · Cited by 99
Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes Mellitus
Kirkman, M. S., Mahmud, H., & Korytkowski, M. T. (2018) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2017.10.002 · Cited by 96
Tebé, C., Martínez-Laguna, D., Carbonell-Abella, C., Reyes, C., Moreno, V. R., Díez‐Pérez, A., Collins, P. G. S., & Prieto‐Alhambra, D. (2019) · Osteoporosis International · doi:10.1007/s00198-019-05122-3 · Cited by 94
Mechanisms of action of metformin with special reference to cardiovascular protection
Zilov, A. V., Abdelaziz, S. I., Alshammary, A., Zahrani, A. A., Amir, A., Khalil, S. H. A., Brand, K. M. G., Elkafrawy, N., Hassoun, A. A. K., Jahed, S. A., et al. (2019) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3173 · Cited by 94
“Finally, metformin did not significantly reduce the incidence of microvascular complications in the randomized or posttrial phases of the UKPDS.(51,54)”
BackgroundInfluentialBergmark, B. A., Bhatt, D. L., McGuire, D. K., Cahn, A., Mosenzon, O., Steg, P. G., Im, K., Kanevsky, E., Gurmu, Y., Raz, I., et al. (2019) · Circulation · doi:10.1161/circulationaha.119.040144 · Cited by 88
Metformin: An old drug against old age and associated morbidities
Salvatore, T., Pafundi, P. C., Morgillo, F., Liello, R. D., Galiero, R., Nevola, R., Marfella, R., Monaco, L., Rinaldi, L., Adinolfi, L. E., et al. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108025 · Cited by 91
GLP-1 receptor agonists in the treatment of type 2 diabetes: role and clinical experience to date
Brunton, S. A., & Wysham, C. H. (2020) · Postgraduate Medicine · doi:10.1080/00325481.2020.1798099 · Cited by 80
Mayberry, L. S., Rothman, R. L., & Osborn, C. Y. (2014) · Journal of Health Communication · doi:10.1080/10810730.2014.938840 · Cited by 95
Tandon, N., Ali, M. K., & Narayan, K. M. V. (2012) · American Journal of Cardiovascular Drugs · doi:10.2165/11594650-000000000-00000 · Cited by 107
“[43] ADVANCE[14] and ACCORD[41] used different strategies and assessed the effects of BP levels lower than the levels achieved in UKPDS.”
BackgroundResultInfluentialDoes Diabetes Double the Risk of Depression?
O'Connor, P. J., Crain, A. L., Rush, W. A., Hanson, A. M., Fischer, L. R., & Kluznik, J. C. (2009) · The Annals of Family Medicine · doi:10.1370/afm.964 · Cited by 86
“Each adult was then categorized in each study year as having diabetes if, in addition to being enrolled in the health plan in the 2 previous years, either of 2 criteria were met in that year: (1) the patient made 1 or more inpatient, or 2 or more outpatient visits having International Classifi cation of Diseases, Nint…”
BackgroundMethodInfluentialA Novel Therapeutic Agent for Type 2 Diabetes Mellitus: SGLT2 Inhibitor
Jung, C. H., Jang, J. E., & Park, J. (2014) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2014.38.4.261 · Cited by 96
Monnier, L., Colette, C., & Owens, D. (2011) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2011.10.014 · Cited by 91
“The results either during the trial periods [1,2] or post-trial monitoring [16,17] indicate clearly that intensive diabetes management with a reduction in total glucose exposure reduces the long-term risk for complications both in type 1 and type 2 diabetes.”
BackgroundInfluentialChoi, H.-C., Kim, S.-J., Son, K. Y., Oh, B., & Cho, B.-L. (2013) · Nutrition · doi:10.1016/j.nut.2013.02.015 · Cited by 107
“Moreover, especially in early DM, interventions can preserve pancreas b cells and improve prognosis [4,6–8].”
BackgroundDiabetic retinopathy, metabolic memory and epigenetic modifications
Kowluru, R. A. (2017) · Vision Research · doi:10.1016/j.visres.2017.02.011 · Cited by 94
Tan, M. Y., Magarey, J. M., Chee, S. S., Lee, L. F., & Tan, M. H. (2011) · Health Education Research · doi:10.1093/her/cyr047 · Cited by 87
“Improving glycaemic control can prevent the onset or delay the progression of micro- and macrovascular complications in diabetes [1, 2].”
BackgroundBedenis, R., Price, A. H., Robertson, C. M., Morling, J. R., Frier, B. M., Strachan, M. W. J., & Price, J. F. (2014) · Diabetes Care · doi:10.2337/dc14-0908 · Cited by 87
Microalbuminuria: A parameter that has changed diabetes care
Parving, H., Persson, F., & Rossing, P. R. (2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2014.10.014 · Cited by 94
Sesa‐Ashton, G., Nolde, J. M., Muente, I., Carnagarin, R., Lee, R., Macefield, V. G., Dawood, T., Sata, Y., Lambert, É., Lambert, G. W., et al. (2023) · Hypertension · doi:10.1161/hypertensionaha.122.20853 · Cited by 88
the Shinken Database Study Group, Nakamura, M., Yamashita, T., Yajima, J., Oikawa, Y., Sagara, K., Koike, A., Kirigaya, H., Nagashima, K., Sawada, H., et al. (2010) · Hypertension Research · doi:10.1038/hr.2010.126 · Cited by 91
The True Value of HbA1c as a Predictor of Diabetic Complications: Simulations of HbA1c Variables
Lind, M., Odén, A., Fahlén, M., & Eliasson, B. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004412 · Cited by 82
“In the post-UKPDS study, the effect of intensive treatment did not become evident until the 10-year follow-up after the end of randomization [12].”
BackgroundInfluentialJafar, T. H., Islam, S., Hatcher, J., Hashmi, S., Bux, R., Khan, A., Poulter, N. R., Badruddin, S. H., & Chaturvedi, N. (2010) · BMJ · doi:10.1136/bmj.c2641 · Cited by 101
“The main limitation of the trial was that its duration was short, so that we cannot tell to what extent changes in blood pressure can be sustained; nor can we speculate on the post-trial impact of the intervention, which has been variable in other trials.”
ResultRuston, A., Smith, A. E., & Fernando, B. (2013) · BMC Public Health · doi:10.1186/1471-2458-13-386 · Cited by 95
Rosenstock, J., Fonseca, V., McGill, J. B., Riddle, M., Hallé, J.-P., Hramiak, I., Johnston, P., & Davis, M. (2009) · Diabetologia · doi:10.1007/s00125-009-1415-7 · Cited by 87
“Clinical trials in patients with type 1 and type 2 diabetes mellitus have established that maintenance of nearnormoglycaemic control reduces the risk of microvascular complications, such as diabetic retinopathy [1–5].”
Screening for Type 2 Diabetes and Dysglycemia
Echouffo-Tcheugui, J. B., Ali, M. K., Griffin, S. J., & Narayan, K. M. V. (2011) · Epidemiologic Reviews · doi:10.1093/epirev/mxq020 · Cited by 94
“Two other points deserve mentioning: 1) very tight glycemic control was shown to be associated with microvascular benefits (243, 244); and 2) the possible lack of benefit in terms of macrovascular risk may not apply to earlier stages of the disease, as indicated by the 10-year results of the UKPDS trial (including peo…”
Current management of diabetes mellitus and future directions in care
Chatterjee, S., & Davies, M. J. (2015) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2014-133200 · Cited by 85
Kanat, M., DeFronzo, R. A., & Abdul-Ghani, M. A. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i12.1207 · Cited by 82
How Low to Go With Glucose, Cholesterol, and Blood Pressure in Primary Prevention of CVD
Hong, K. N., Fuster, V., Rosenson, R. S., Rosendorff, C., & Bhatt, D. L. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.09.001 · Cited by 80
“This has been termed the legacy effect (37).”
BackgroundUnderstanding Metabolic Memory: A Tale of Two Studies
Miller, R. G., & Orchard, T. J. (2020) · Diabetes · doi:10.2337/db19-0514 · Cited by 89
“A similar effect has also been observed in type 2 diabetes, where it was referred to as a “legacy effect” (8,9).”
BackgroundEndocrine Function Impairment After Distal Pancreatectomy: Incidence and Related Factors
Kang, J. S., Jang, J., Kang, M. J., Kim, E.-J., Jung, W., Chang, J., Shin, Y., Han, Y., & Kim, S. (2015) · World Journal of Surgery · doi:10.1007/s00268-015-3228-9 · Cited by 90
Metadata
- Authors
- Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W.
- Affiliations
- Churchill Hospital (GB)
- Oxford Centre for Diabetes, Endocrinology and Metabolism (GB)
- NIHR Oxford Biomedical Research Centre (GB)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2008-10-09
- Volume
- 359
- Issue
- 15
- Pages
- 1577-1589
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2171294019
- Semantic Scholar
- 796f87021518c0bff851ff1ade5f780e3569e4ae
- Cited by
- 7,751
- References
- 55
- Citations by year
- 2026: 194 · 2025: 243 · 2024: 322 · 2023: 387 · 2022: 430 · 2021: 441 · 2020: 451 · 2019: 420 · 2018: 442 · 2017: 480 · 2016: 535 · 2015: 511 · 2014: 529 · 2013: 474 · 2012: 482
- FWCI
- 337.60
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Wellcome Trust
- National Institute for Health and Care Research
- British Heart Foundation
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 2 diabetes, tight glycemic control, glycemic control, metformin, sulfonylureas, insulin therapy, dietary therapy, microvascular complications, macrovascular outcomes, myocardial infarction, mortality, HbA1c, post-trial follow-up, UKPDS
- MeSH terms
- Aged, Blood Glucose, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Female, Follow-Up Studies, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Insulin, Male, Metformin, Middle Aged, Myocardial Infarction, Risk, Sulfonylurea Compounds, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.